CYTOKINETICS INC
For the period ended Mar 31, 2024. Filed May 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 10, 2024
CYTK$56.18+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands) (Unaudited)
| Three Months Ended | ||
|---|---|---|
| March 31, 2024 | March 31, 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(135,643) | $(131,289) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Non-cash interest expense on liabilities related to revenue participation right purchase agreements | 10,244 | 6,313 |
| Stock-based compensation expense | 21,612 | 15,194 |
| Non-cash lease expense | 995 | 935 |
| Depreciation of property and equipment | 2,331 | 1,848 |
| Realized gain on investment, net | — | 34 |
| Interest receivable and amortization on investments | (5,224) | (3,037) |
| Non-cash interest expense related to debt | 1,879 | 6,888 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 449 | (859) |
| Prepaid and other assets | (6,630) | (1,627) |
| Accounts payable | (10,294) | (8,106) |
| Accrued and other liabilities | (5,579) | (7,755) |
| Operating lease liabilities | (1,712) | (120) |
| Other non-current liabilities | (1,935) | (705) |
| Net cash used in operating activities | (129,507) | (122,286) |
| Cash flows from investing activities: | ||
| Purchases of investments | (142,655) | (89,779) |
| Maturities of investments | 175,296 | 250,701 |
| Sales of investments | — | 4,977 |
| Purchases of property and equipment | — | (402) |
| Net cash provided by investing activities | 32,641 | 165,497 |
| Cash flows from financing activities: | ||
| Repayment of finance lease liabilities | (227) | (207) |
| Repayment of term loan | (705) | — |
| Proceeds from issuance of common stock related to at-the-market offering, net of issuance costs | 93,640 | — |
| Proceeds from issuance of common stock under equity incentive and stock purchase plans | 29,532 | 3,547 |
| Taxes paid related to net share settlement of equity awards | (18,449) | (10,517) |
| Net cash provided by (used in) financing activities | 103,791 | (7,177) |
| Effect of exchange rate changes | 27 | — |
| Net increase in cash, cash equivalents, and restricted cash | 6,952 | 36,034 |
| Cash, cash equivalents, and restricted cash, beginning of period | 113,399 | 67,182 |
| Cash, cash equivalents, and restricted cash, end of period | $120,351 | $103,216 |
| Supplemental cash flow disclosures: | ||
| Cash paid for interest | $10,206 | $40 |
| Non-cash investing and financing activities: | ||
| Right-of-use assets recognized in exchange for operating lease obligations | $178 | $— |
| Amounts unpaid for purchases of property and equipment | $1,754 | $473 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.